Patents Assigned to Thar Pharmaceuticals
  • Crystalline forms of lamotrigine
    Patent number: 8486927
    Abstract: The invention is directed to novel crystalline forms of lamotrigine. These novel crystalline forms of lamotrigine have improved dissolution and in-vivo absorption profile, as compared to pure lamotrigine. These novel crystalline forms of lamotrigine provide a substantial increase in the blood concentration of lamotrigine, as compared to pure lamotrigine when administered to a subject. These novel crystalline forms of lamotrigine also provide a slower, steady build up of lamotrigine blood concentration suitable for sustained release of lamotrigine in-vivo, as compared to pure lamotrigine.
    Type: Grant
    Filed: November 10, 2008
    Date of Patent: July 16, 2013
    Assignee: Thar Pharmaceuticals
    Inventors: Mazen Hanna, Ning Shan, Miranda L. Cheney
  • In vivo studies of crystalline forms of meloxicam
    Patent number: 8389512
    Abstract: The invention is directed to novel crystalline forms of meloxicam. These novel crystalline forms of meloxicam have improved bioavailability, an enhanced rate of dissolution and shorter time to Cmax in blood, as compared to pure meloxicam.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: March 5, 2013
    Assignee: Thar Pharmaceuticals
    Inventors: Mazen Hanna, Ning Shan, Miranda L. Cheney, David R. Weyna
  • In Vivo Studies of Crystalline Forms of Meloxicam
    Publication number: 20120149692
    Abstract: The invention is directed to novel crystalline forms of meloxicam. These novel crystalline forms of meloxicam have improved bioavailability, an enhanced rate of dissolution and shorter time to Cmax in blood, as compared to pure meloxicam.
    Type: Application
    Filed: February 17, 2012
    Publication date: June 14, 2012
    Applicant: THAR PHARMACEUTICALS
    Inventors: Mazen Hanna, Ning Shan, Miranda L. Cheney, David R. Weyna
  • In vivo studies of crystalline forms of meloxicam
    Patent number: 8124603
    Abstract: The invention is directed to novel crystalline forms of meloxicam. These novel crystalline forms of meloxicam have improved bioavailability, an enhanced rate of dissolution and shorter time to Cmax in blood, as compared to pure meloxicam.
    Type: Grant
    Filed: January 22, 2009
    Date of Patent: February 28, 2012
    Assignee: Thar Pharmaceuticals
    Inventors: Mazen Hanna, Ning Shan, Miranda L. Cheney, David R. Weyna
  • In vivo studies of crystalline forms of meloxicam
    Publication number: 20090203680
    Abstract: The invention is directed to novel crystalline forms of meloxicam. These novel crystalline forms of meloxicam have improved bioavailability, an enhanced rate of dissolution and shorter time to Cmax in blood, as compared to pure meloxicam.
    Type: Application
    Filed: January 22, 2009
    Publication date: August 13, 2009
    Applicant: Thar Pharmaceuticals
    Inventors: Mazen Hanna, Ning Shan, Miranda L. Cheney, David R. Weyna
  • Crystalline Forms of lamotrigine
    Publication number: 20090176787
    Abstract: The invention is directed to novel crystalline forms of lamotrigine. These novel crystalline forms of lamotrigine have improved dissolution and in-vivo absorption profile, as compared to pure lamotrigine. These novel crystalline forms of lamotrigine provide a substantial increase in the blood concentration of lamotrigine, as compared to pure lamotrigine when administered to a subject. These novel crystalline forms of lamotrigine also provide a slower, steady build up of lamotrigine blood concentration suitable for sustained release of lamotrigine in-vivo, as compared to pure lamotrigine.
    Type: Application
    Filed: November 10, 2008
    Publication date: July 9, 2009
    Applicant: Thar Pharmaceuticals
    Inventors: Mazen Hanna, Ning Shan, Miranda L. Cheney